APS Workshop at DDL2022

NASAL BIOPHARMACEUTICS: fit for current and future drug delivery needs?

The APS workshop took place during the morning of  Wednesday 7th December at the EICC, before the main DDL2022 conference.

A number of the scientific and regulatory hurdles that exist for developing and registering new nasally-delivered therapies provide common challenges across the pharmaceutical industry. This meeting represents an opportunity to bring together members of the scientific community across industry and academia to discuss specific biopharmaceutics challenges around the development of nasally administered therapies. Aims of the symposium include exploring the need for a network for regular meetings and collaboration, and the development of a consensus of the state-of-the–art in nasal biopharmaceutics.

The symposium will feature thought-provoking short talks summarising how we currently assess the biopharmaceutical properties and performance of nasal products with a focus on new developments and unmet needs. This will be followed by a facilitated panel discussion to explore current practices, opportunities and challenges in these areas. Any questions regarding the workshop programme may be directed to Ben Forbes, King’s College London ([email protected]).

You can view the presentation slides from each presenter below, by clicking on the title of their talk.

09:00 - 09:05


Ben Forbes, Chair

09:05 - 09:20

Nasal biopharmaceutics: current and new methods for characterisation

  • The T4N concept
  • Developments in in vitro testing of nasal products
  • Assessment of < 10 µm fraction

Regina Scherließ, Kiel University

09:20 - 09:40

Physiologically-based biopharmaceutics modelling for nasal delivery

  • Applications of PBBM modelling in nasal drug delivery
  • Current status of nasal PBBM models
  • Future opportunities/call to action

Claire Patterson, SEDA

09:40 - 10:00

Modelling deposition in the nasal cavity

  • In silico models
  • In vitro methods
  • Realistic and idealised geometries

Andrew Martin, University of Alberta

10:00 - 10:20

In vitro biopharmaceutical characterisation

  • Cell models of the nasal cavity
  • Role of mucus
  • Role of mucociliary clearance

Alison Lansley, University of Brighton

11:00 - 11:20

Preclinical models and translation

• Nasal delivery study trends
• Pre-clinical development for nasally administered medicines
• Practicalities of nasal studies and future developments in study design and           methods

Helen Palmer, Labcorp

11:20 - 11:40

Clinical development

  • Scintigraphic / MRI imaging and analysis of nasal delivery
  • Product and device performance evaluations
  • Nasal wick evaluations

Chris Roe, Quotient

11:40 - 12:00

Panel discussion

  • Gaps in biopharmaceutics for nasal delivery
  • Future directions and gap analysis:
  • Challenges and opportunities

All presenters

We're sorry, but all tickets sales have ended because the event is expired.